As filed with the Securities and Exchange Commission on February 29, 2024
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-8
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
4D Molecular Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
| Delaware | 47-3506994 | |
(State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.) | |
5858 Horton Street #455 Emeryville, California 94608 (510) 505-2680 | 94608 | |
| (Address of Principal Executive Offices) | (Zip Code) | |
2020 Incentive Award Plan
2020 Employee Stock Purchase Plan
(Full title of the plan)
David Kirn, M.D.
Chief Executive Officer
4D Molecular Therapeutics, Inc.
5858 Horton Street #455
Emeryville, California 94608
(Name and address of agent for service)
(510) 505-2680
(Telephone number, including area code, of agent for service)
Copies to:
Mark V. Roeder, Esq.
Phillip S. Stoup, Esq.
Latham & Watkins LLP
140 Scott Drive
Menlo Park, CA 94025
(650) 328-4600
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
| Large accelerated filer | ☐ | Accelerated filer | ☐ | |||
| Non-accelerated filer | ☒ | Smaller reporting company | ☒ | |||
| Emerging growth company | ☒ | |||||
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐
EXPLANATORY NOTE
This Registration Statement on Form S-8 is being filed by 4D Molecular Therapeutics, Inc. (the “Registrant”) for the purpose of registering an additional 2,153,533 shares of the Registrant’s common stock, par value $0.0001, issuable under the 2020 Incentive Award Plan as a result of the operation of an automatic annual increase provision therein, and 50,000 shares of the Registrant’s common stock, par value $0.0001, issuable under the 2020 Employee Stock Purchase Plan pursuant to the annual increase provision therein.
INCORPORATION BY REFERENCE OF CONTENTS OF REGISTRATION STATEMENT ON FORM S-8
Pursuant to General Instruction E of Form S-8, the contents of the Registration Statements on Form S-8 filed with the Securities and Exchange Commission (the “Commission”) on December 15, 2020 (File No. 333-251370), March 25, 2021 (File No. 333-254701), March 28, 2022 (File No. 333-263908) and March 15, 2023, as amended on May 4, 2023, (File No. 333-270566) are incorporated by reference herein.
Item 8. Exhibits.
EXHIBIT INDEX
Incorporated by Reference | ||||||||||
Exhibit Number | Description | Form | Exhibit | Date Filed | Filed Herewith | |||||
| 4.1 | Amended and Restated Certificate of Incorporation of 4D Molecular Therapeutics, Inc. | 8-K | 3.1 | 12/15/2020 | ||||||
| 4.2 | Amended and Restated Bylaws of 4D Molecular Therapeutics, Inc. | 8-K | 3.1 | 11/22/2023 | ||||||
| 4.3 | Form of Common Stock Certificate. | S-1/A | 4.2 | 12/07/2020 | ||||||
| 5.1 | Opinion of Latham & Watkins LLP. | X | ||||||||
| 23.1 | Consent of Latham & Watkins LLP (included in Exhibit 5.1). | X | ||||||||
| 23.2 | Consent of Independent Registered Public Accounting Firm. | X | ||||||||
| 24.1 | Power of Attorney (included in the signature page to this registration statement). | X | ||||||||
| 99.1(a)# | 4D Molecular Therapeutics, Inc. 2020 Incentive Award Plan. | S-8 | 99.2(a) | 12/15/2020 | ||||||
| 99.1(b)# | Form of Stock Option Grant Notice and Stock Option Agreement under the 2020 Incentive Award Plan. | S-1/A | 10.2(b) | 12/07/2020 | ||||||
| 99.2# | 4D Molecular Therapeutics, Inc. 2020 Employee Stock Purchase Plan. | S-8 | 99.3 | 12/15/2020 | ||||||
| 107.1 | Calculation of Filing Fee Table | X | ||||||||
| # | Indicates management contract or compensatory plan. |
Pursuant to the requirements of the Securities Act, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Emeryville, State of California, on February 29, 2024.
| 4D Molecular Therapeutics, Inc. | ||
| By: | /s/ Uneek Mehra | |
| Uneek Mehra | ||
| Chief Financial and Business Officer | ||
POWER OF ATTORNEY
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints David Kirn, M.D. and Uneek Mehra, and each of them acting individually, as his or her true and lawful attorneys-in-fact and agents, each with full power of substitution, for him or her in any and all capacities, to sign any and all amendments to this Registration Statement, including post-effective amendments or any abbreviated registration statement and any amendments thereto filed, with all exhibits thereto and other documents in connection therewith, with the SEC, granting unto said attorneys-in-fact and agents, with full power of each to act alone, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully for all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or his or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Act, this Registration Statement has been signed by the following persons in the capacities and on the date indicated.
Signature | Title | Date | ||||
/s/ David Kirn | ||||||
| David Kirn, M.D. | Chief Executive Officer and Director (Principal Executive Officer) | February 29, 2024 | ||||
/s/ Uneek Mehra | ||||||
| Uneek Mehra | Chief Financial and Business Officer (Principal Financial and Accounting Officer) | February 29, 2024 | ||||
/s/ John F. Milligan | ||||||
| John F. Milligan, Ph.D. | Executive Chairman | February 29, 2024 | ||||
/s/ Jacob Chacko | ||||||
| Jacob Chacko, M.D., MBA | Director | February 29, 2024 | ||||
/s/ Susannah Gray | ||||||
| Susannah Gray, MBA | Director | February 29, 2024 | ||||
/s/ Nancy Miller-Rich | ||||||
| Nancy Miller-Rich | Director | February 29, 2024 | ||||
/s/ Charles P. Theuer | ||||||
| Charles P. Theuer, M.D., Ph.D. | Director | February 29, 2024 | ||||
/s/ Shawn Cline Tomasello | ||||||
| Shawn Cline Tomasello, MBA | Director | February 29, 2024 | ||||
